Article Text

PDF
Correspondence
HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?
  1. Tatiana Ignatova,
  2. Olga Chernova,
  3. Pavel Novikov,
  4. Sergey Moiseev
  1. Clinic of Nephrology, Internal and Occupational Diseases, First Moscow State Medical University, Moscow, Russia
  1. Correspondence to Professor Sergey Moiseev, Clinic of Nephrology, Internal and Occupational Diseases, First Moscow State Medical University, Rossolimo, 11/5, Moscow 119992, Russia; clinpharm{at}mtu-net.ru

Statistics from Altmetric.com

Mixed cryoglobulinaemia (MC) vasculitis is a relatively uncommon systemic vasculitis that may be primary or associated with hepatitis C virus (HCV). We have found MC and cryoglobulinaemic vasculitis in 420 (31%) and 65 (5%) of 1351 patients with HCV infection, respectively. Two recent randomised controlled trials have established the superiority of rituximab over conventional immunosuppressive treatment in patients with MC vasculitis1 ,2 while Saadoun et al3 have previously shown that dual antiviral treatment with interferon α and ribavirin had induced remission of HCV-associated MC vasculitis in 63% of 72 consecutive patients and sustained virological response in 58% of cases. In a study recently published in the Annals of the Rheumatic Diseases,4 the same authors suggested that triple antiviral treatment with peginterferon-α–ribavirin–protease inhibitor was highly …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles